Discontinued — last reported Q4 '24
INGREZZA — Total revenues
Neurocrine Biosciences INGREZZA — Total revenues remained flat by 0.0% to $575.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 27.8%, from $450.00M to $575.00M. Over 2 years (FY 2022 to FY 2024), INGREZZA — Total revenues shows an upward trend with a 28.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful commercial execution, or expanded patient access, while a decrease may signal increased competition, patent cliffs, or market saturation.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product within the c...
Peer comparison
Comparable to product-specific net sales reported by other biopharmaceutical companies, often benchmarked against therapeutic area peers or blockbuster drug performance metrics.
nbix_segment_ingrezza_total_revenuesHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $1.40B | $1.80B | $2.30B |
| YoY Change | — | +28.6% | +27.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's ingrezza — total revenues?
- Neurocrine Biosciences (NBIX) reported ingrezza — total revenues of $575.00M in Q4 2024.
- How has Neurocrine Biosciences's ingrezza — total revenues changed year-over-year?
- Neurocrine Biosciences's ingrezza — total revenues increased by 27.8% year-over-year, from $450.00M to $575.00M.
- What is the long-term trend for Neurocrine Biosciences's ingrezza — total revenues?
- Over 2 years (2022 to 2024), Neurocrine Biosciences's ingrezza — total revenues has grown at a 28.2% compound annual growth rate (CAGR), from $1.40B to $2.30B.
- What does ingrezza — total revenues mean?
- The total sales revenue generated by a specific drug product.